#POLB Poolbeg Pharma – Result of AGM
4 April 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that at the Annual General Meeting held at 11:00am today, all resolutions were duly passed with in excess of 99.9% approval. -Ends- Enquiries Poolbeg Pharma Plc Jeremy Skillington, CEO Ian […]
Poolbeg Pharma #POLB – POLB 001 Clinical Development – Clinical Trial Agreement Signed
31 March, 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’) announces that it has signed a Clinical Trial Agreement with the Centre for Human Drug Research (CHDR) in the Netherlands for the completion of a bacterial lipopolysaccharide (‘LPS’) human challenge study of POLB 001, which is due to commence in June […]
Poolbeg Pharma #POLB commences trading on OTCQB Market in the United States
30 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that trading in the Company’s Ordinary Shares of nominal value of £0.02 each (“Ordinary Shares”) will commence today on the OTCQB Venture Market in the United States. The […]
#POLB Poolbeg Pharma – Artificial Intelligence deal signed with CytoReason
24 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has signed a deal with CytoReason, a leading artificial intelligence (AI) company developing computational disease models for efficient drug discovery and development, to provide AI analysis of Poolbeg’s influenza […]
#ORPH Open Orphan – Open Orphan plc distribution in specie of Poolbeg Pharma plc shares – FAQ
When will I receive my share certificate? The Poolbeg Pharma shares received are subject to a lock-up period that ends on 19 April 2022. Within 14 days of that date, shareholders will be sent a certificate for their distribution in specie shares. Shareholders will then have the option to dematerialise the shares and hold via […]
Alan Green covers #POLB Poolbeg Pharma, #NTOG Nostra Terra O&G and #MNRG MetalNRG on the Vox Market Podcast
Alan Green covers #POLB Poolbeg Pharma, #NTOG Nostra Terra O&G and #MNRG MetalNRG on the Vox Market Podcast Listen to the podcast here
#POLB Poolbeg Pharma – POLB sign AI discovery deal with OneThree Biotech for first human challenge trial
POLB’s CEO Jeremy Skillington & One Three Biotech‘s co-founder & COO Brad Pryde catch up with @proactive_UK to discuss the recent AI deal to identify new drugs & treatments for RSV.
Poolbeg Pharma #POLB – 2021 Annual Report and 2022 AGM Notice
Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model , announces that its Annual Report and Accounts for the period ended 31 December 2021, a notice of the Annual General Meeting (“AGM”) 2022 and voting proxy form have been posted to shareholders. […]
#POLB Poolbeg Pharma – Final Results
Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) announces its audited results for the period ended 31 December 2021. These results follow the Company’s spin-out from Open Orphan plc and the subsequent listing on the AIM market of the London Stock Exchange in July 2021. Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a […]
Poolbeg Pharma #POLB – Interview
Co-founder & #COO of One Three Biotech, Brad Pryde catches up with brr mediauk on the #AI Deal with #POLB Poolbeg Pharma to identify new #drugs & treatments for #RSV. https://www.youtube.com/watch?v=TnKrI6xCt4s&ab_channel=PoolbegPharma